Proteomics &Metabolomics Shared Resource Molecular characterization of disease processes has become an indispensable component of current cancer research. The mission of this Shared Resource is to provide state-of-the-art chromatographic and mass spectrometric services for proteomic and metabolomic applications. The Proteomics and Metabolomics Shared Resource (PMSR) was established in 2006 for proteomics and was expanded to metabolomics in 2008. Since the last review, the activity and throughput of the PMSR has expanded dramatically;PMSR provided services to 20 Lombardi members in 2012. Radoslav Goldman, PhD, oversees the proteomics operations while the metabolomics component is managed by Amrita Cheema, PhD and Albert Fornace, MD. Proteomics services include optimization of proteomic workflows and development of specialized services including identification of proteins/peptides and their modifications as well as their quantification. Quantitative LC-MS-SRM isotope dilution experiments for the analysis of peptides and their modifications facilitate conduct of translational research applications. The QSTAR Elite mass analyzer was upgraded in 2012 to the 5600 QTOF to provide high resolution and speed of analysis required for current cancer research. The metabolomics component includes comprehensive metabolomic and lipidomic profiling services from a variety of matrices including tissue and cultured cells as well as biofluids such as serum, plasma and urine. The PMSR has developed and optimized methods for metabolite extraction from complex matrices such as cells, feces, ductal lavage fluid and cerebrospinal fluid. The metabolomics services also include multiple reaction monitoring based targeted quantification as well as high-resolution mass spectrometry for small molecules. A GC mass spectrometer was added 12/2012. The metabolomics component was recognized as a Center of Innovation by Waters Corporation. Genomics &Epigenomics Shared Resource The various "omic" technologies have emerged relatively recently and evolved rapidly, becoming essential to almost every aspect of cancer research. In view of this, the Genomics &Epigenomics Shared Resource (GESR) is an indispensable Shared Resource for the Georgetown Lombardi Comprehensive Cancer Center (LCCC). The objective of the GESR is to provide investigators with diverse state-of-the-art services for genomic and epigenomic studies such as gene expression profiling, single nucleotide polymorphism (SNP) genotyping, copy number variation (CNV) analysis and DNA methylation. Since the last competitive review, the Shared Resource has been expanded with the upgrade of these services for genome-wide studies and the addition of new services including miRNA expression profiling, next-generation sequencing, label-free molecular interaction analysis and siRNA screening. To facilitate these services, the GESR assists users in DNA/RNA extraction and quality assessment, DNA plating and assay preparation. In 2012, the GESR provided services to 38 LCCC members frcm all four Research Programs;82% of these investigators are funded through peer-reviewed grants. The GESR supported 72 manuscripts published in peer-reviewed journals in the funding period. The Resource Director, Habtom W. Ressom, PhD, has experience in designing and developing workflows to ensure reproducible "omic" experiments. He is responsible for oversight of the GESR overall services, staff, budget, policies and strategic planning. The Resource Assistant Director, Aykut Uren, MD, is expert in surface plasmon resonance (SPR) technologies and their application for measurement of the concentrations of specific molecules and determination of intermolecular interactions. The Director of Operations, David S. Goeriitz, MS, has extensive training and experience in genomic and epigenomic technologies and assays. He manages the day-to-day operations of the GESR and assists investigators with assay design and experimental setup.

Public Health Relevance

Genomics &Epigenomics Shared Resource Genome-scale analysis techniques such as microarray and next-generation sequencing, and measurements of molecular interactions have enabled advances in understanding the molecular mechanisms underlying the initiation and progression of cancer. They also provide information necessary to advance the field of cancer epigenomics, modifications to the DNA like methylation and modification of expression by miRNAs, for improved diagnosis, prognosis, and treatment response. Proteomics &Metabolomics Shared Resource Proteomics, the characterization of proteins and their cancer-related modifications, and metabolomics, the assessment of metabolism and other small molecule changes during carcinogenesis and in response to cancer treatment, are key methodologies in the study of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
United States
Zip Code
Bae, Woo Kyun; Yoo, Kyung Hyun; Lee, Ji Shin et al. (2015) The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol Carcinog 54:1172-80
Adams, Inez; Christopher, Juleen; Williams, Karen Patricia et al. (2015) What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2. J Cancer Educ 30:344-52
Butrick, Morgan; Kelly, Scott; Peshkin, Beth N et al. (2015) Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genet Med 17:467-75
London, Laricca; Hurtado-de-Mendoza, Alejandra; Song, Minna et al. (2015) Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors. Contemp Clin Trials 40:74-80
Mays, Darren; Niaura, Raymond S; Evans, W Douglas et al. (2015) Cigarette packaging and health warnings: the impact of plain packaging and message framing on young smokers. Tob Control 24:e87-92
Zhi, Xiuling; Lin, Ling; Yang, Shaoxian et al. (2015) ?II-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology 61:598-612
Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18
Heckler, Mary Mazzotta; Riggins, Rebecca B (2015) ERR? splice variants differentially regulate cell cycle progression. Cell Cycle 14:31-45
Kim, B; Wang, S; Lee, J M et al. (2015) Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34:1083-93
Tong, Angie; Kelly, Scott; Nusbaum, Rachel et al. (2015) Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology 24:33-9

Showing the most recent 10 out of 544 publications